WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/142421    International Application No.:    PCT/KR2009/002617
Publication Date: 26.11.2009 International Filing Date: 18.05.2009
A61K 9/22 (2006.01), A61K 9/00 (2006.01), A61K 9/48 (2006.01), A61K 9/16 (2006.01), A61K 31/616 (2006.01), A61K 31/44 (2006.01)
Applicants: HANALL BIOPHARMA CO., LTD [KR/KR]; 400-1, Sangseo-dong, Daedeok-gu Daejeon 306-120 (KR) (For All Designated States Except US).
KIM, Sung Wuk [KR/KR]; (KR) (For US Only).
JUN, Sung Soo [KR/KR]; (KR) (For US Only).
LEE, Ah Ram [KR/KR]; (KR) (For US Only).
PARK, Yun Sang [KR/KR]; (KR) (For US Only)
Inventors: KIM, Sung Wuk; (KR).
JUN, Sung Soo; (KR).
LEE, Ah Ram; (KR).
PARK, Yun Sang; (KR)
Agent: AHN, So-Young; (KR)
Priority Data:
10-2008-0045833 17.05.2008 KR
(KO) 약제학적 제제
Abstract: front page image
(EN)The present invention provides a pharmaceutical preparation which comprises: an early release zone containing an HMG-CoA reductase inhibitor as a pharmacological active component; and a delayed release zone containing a fibric acid derivative as a pharmacological active component. The pharmaceutical preparation of the present invention is designed in such a way as to allow the controlled release of drugs over a specific time period and at a specific rate, and is highly efficacious in the treatment of hyperlipidaemia.
(FR)L'invention concerne une préparation pharmaceutique qui comprend : une zone de libération précoce contenant un inhibiteur de la réductase HMG-CoA comme composant pharmacologique actif; et une zone de libération différée contenant un dérivé d'acide fibrique comme composant pharmacologique actif. La préparation pharmaceutique de l'invention est conçue de façon à permettre la libération contrôlée de médicaments pendant une durée spécifique et à un débit spécifique, et est très efficace pour traiter l'hyperlipidémie.
(KO)본 발명은 약리학적 활성성분으로 HMG-CoA 환원효소 저해제를 포함하는 선방출성 구획, 및 약리학적 활성성분으로 피브린산 유도체를 포함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 약제학적 제제는 특정 시간 및 속도로 약물을 제어방출하도록 설계되어, 고지혈증 치료에 매우 효과적이다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)